Introduction
The major histocompatibility complex (MHC) class I loci include classical and non-classical genes. The classical HLA-A, -B and -C genes encode glycoproteins that bind intracellular peptides and present them to cytotoxic T cells (Townsend et al., 1986) . The non-classical HLA-E, -F, and -G products do not exhibit either the polymorphism (Geraghty et al., 1987; Alizadeh et al., 1993; Morales et al., 1993; Arnaiz-Villena et al., 1997) or the widespread tissue distribution of classical MHC class I molecules (Wei & Orr, 1990) , and their functions are now being studied. The presence of HLA-G transcripts has been demonstrated in a wide variety of cells in foetal and adult tissues. Although the levels of mRNA detected were very low and could merely reflect a basal transcription without physiological significance, it is interesting to study HLA-G gene expression in different pathological circumstances. Recently, reliable monoclonal antibodies have been shown to detect HLA-G on the cell surface (Crisa et al., 1997; Perez-Villar et al., 1997) . Receptors on natural killer (NK) cells that recognize HLA-G have been identified (Pazmany et al., 1996; Münz et al., 1997; Pende et al., 1997; Perez-Villar et al., 1997; ) ; the latter seem to be involved in protecting the trophoblast from recognition by NK and T cells (Arnaiz-Villena et al., 1997) . In fact, Mhc-G and -E molecules may only use endogenous peptides to reach the cell surface and induce tolerance inhibiting the cytolytic responses of NK and T cells (Arnaiz-Villena et al., 1997) . Seven different HLA-G subtypes (HLA-G*01011, G*01012, G*0102, G*01013, G*0103, G*0104 and G*0105N) have been defined by the WHO Nomenclature Committee for Factors of the HLA System (Bodmer et al., 1997) .
Materials and methods
An HLA-G sequencing study of cDNA molecules was carried out to investigate the alternative HLA-G splicing in human thyroid follicular cells (TFC) from surgically removed Graves' disease-affected glands. Cells were obtained as previously described (Pujol-Borrel et al., 1983; Sospedra et al., 1997) after digestion of the glands and culture of the resulting cells for 48 h. Five patients' samples were analysed and a normal thyroid cell line (HT93, Belfiore et al., 1991) was used as a control. This work was done within a more general project designed to investigate a possible de novo expression of non-classical HLA class I antigens and the role of NK and T cells in causing thyroid inflammation (Bottazzo et al., 1988) . Four alternative splices previously described for HLA-G have been found and a complete sequence of the HLA-G*01012 allele, including exons 2, 3, 4, 5, 6 and 8, has been obtained. Total RNA from TFC was extracted using the standard method (Chomczinsky & Sacchi, 1987) . Synthesis of cDNA from total RNA was performed using oligo-dT as a primer, as previously described (Sospedra et al., 1997) . In order to amplify the HLA-G cDNA, and since the gene message is represented at a very low level, two rounds of polymerase chain reaction (PCR), using nested sets of primers, were necessary. The first round of PCR was carried out using primers GC1.2a: 5'CCC TGA CCC TGA CCG AGA CCT GGG and G3'UT: 5'CCA TCA ATC TCT CTT GGA corresponding to the exon 1 and 3'UT regions, respectively. The second round of PCR amplification used primers located inside those used in the first reaction; G2-5': 5'TCC ATG AGG TAT TTC AGC GC and GC2a: 5'GGC TGG TCT CTG CAC AAA GAG A placed at the exon 2 and 3'UT regions, respectively. A total of 1.25 µL of cDNA product, 25 pM of the primers GC1.2a and G3'UT, 1.25 units of Taq polymerase (Ampli-taq, Perkin Elmer-Cetus), 18.6 µL of a premix of PCR buffer, and 200 µM of each nucleotide were subjected to the following conditions for the first PCR reaction: 5 min denaturation at 94°C, 40 cycles of 20 s denaturation at 94°C, 60 s annealing at 55°C, 75 s extension at 72°C, and a final polymerization step at 72°C for 10 min. A total of 1 µL of the first PCR reaction was then transferred to 49 µL of a PCR buffer premix as above but containing the second primer sets. A further 40 cycles of amplification were carried out (94°C for 20 s, 56°C for 20 s and 72°C for 75 s). No amplification product was detected in the normal thyroid cell line. However, different size products from the Graves' samples were obtained (see Fig. 1c ). Products from two samples (TB250 and TB270) were purified, inserted into the pMOS Blue-T vector, and sequenced in an Applied Biosystem (Foster City, CA) DNA automated sequencer (Arnaiz-Villena et al., 1992) .
Results
Six alternative splicing forms of HLA-G transcripts have been described (Ishitani & Geraghty, 1992; Fujii et al., 1994) and only four different splices have been found in this study ( Fig. 1) : HLA-G1, the larger mRNA that is devoid of exon 7, and three smaller forms that result from splicing out exons 3 and 7 (HLA-G2), exons 3, 4 and 7 (HLA-G3), and exon 4 and 7 (HLA-G4). All these isoforms show an in-frame stop codon at the second codon of exon 6 (Geraghty et al., 1987; Shukla et al., 1990) . However, soluble HLA-G5 and -G6 splicing forms, which retain intron 4 and have been observed in trophoblastic cells (Fujii et al., 1994; Kirszenbaum et al., 1994; Arnaiz-Villena et al., 1997) , have not been found in TFC. When the DNA sequences obtained from the largest isoform were sequenced, two HLA-G alleles were obtained: one of them is identical to the HLA-G*01011 allele previously sequenced from genomic DNA (Geraghty et al., 1987) or cDNA (Shukla et al., 1990) , and the other is identical to HLA-G*01012, whose exons 2 and 3 were previously sequenced from genomic DNA (Castro et al., 1996) . Exons 4, 5, 6 and 8 of this allele are identical to those obtained from the BeWo cell line by Ellis et al. (1990) . Only four changes, all of them synonymous (Fig. 2) , have been found when comparing HLA-G*01011 with HLA-G*01012: CCG (proline) to CCA at position 57, CAC (histidine) to CAT at position 93, GGC (glycine) to GGT at position 290 and AGA (arginine) to AGG at position 310.
Discussion
(1) Four of the six HLA-G splicing isoforms have been found in human pathological thyroid follicular cells. Functional implications of this finding should be further studied, particularly with regard to inflammation and NK and T cell activity. No soluble isoforms have been found in these cells, and further studies are necessary to see if only some of the G molecules (i.e. soluble isoforms) are the tolerogenic ones. Soluble G molecules may help to control inflammation and their absence may be responsible in part for the ongoing inflammation in Graves' TFC. (2) The HLA-G*01011 allele cDNA sequence has been confirmed. (3) The HLA-G*01012 allele cDNA has also been sequenced, including exons 2, 3, 4, 5, 6 and 8, and four nucleotide differences have been found with respect to the HLA-G*01011 allele. These differences are synonymous changes; this suggests that evolutionary pressure tends to keep HLA-G unchanged. However, stop codons, or deletions that change the normal reading frame, have been found in homozygosity in Cercophitecinae monkeys (Boyson et al., 1996; Castro et al., 1996) and heterozygosity in humans (Van Der Ven & Ober, 1994) , suggesting that it could be a pseudogene. Alternative splicing isoforms that lack exons with stop codons could yield functional proteic products, i.e. isoforms bearing α1 domain (exon 2) may be the functional ones, because they exist in all Mhc-G DNA sequences obtained from all human and ape individuals tested so far. It is possible that Mhc-G may inhibit NK cells close to the placenta, since HLA-G is able to inhibit NK activity (Carosella et al., 1996; Pazmany et al., 1996) . This inhibition may be more efficient if soluble HLA-G forms are involved. In addition, suppressor T cells bearing CD8 may also recognize cytotrophoblast cells and induce local immune suppression. Both NK inhibition and suppressor T-cell activation induced locally by HLA-G molecules on placental cells may be a crucial mechanism in avoiding foetal rejection until delivery.
